NCT05203692View on ClinicalTrials.gov

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

January 25, 2023

Study Completion Date

March 22, 2023

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

DS-7011a

Intravenous or subcutaneous administration, single dose

DRUG

Placebo

Intravenous or subcutaneous administration, single dose

Trial Locations (2)

78217

Worldwide Clinical Trials, San Antonio

90806

Apex Clinical Research (Collaborative Neuroscience Research), Long Beach

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY